GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Boundless Bio Inc.
Shares of Boundless Bio, an oncology company focused on treating cancers caused by extrachromosomal DNA, reflect the potential of its innovative approach. The trajectory of its price after the IPO will depend on the success of clinical trials.
Share prices of companies in the market segment - Dna
Boundless Bio is a biopharmaceutical company developing targeted therapies for the treatment of cancers caused by extrachromosomal DNA (ecDNA) amplification. We've classified this DNA as "DNA." The chart below shows how the market is pricing new approaches to cancer treatment.
Broad Market Index - GURU.Markets
Boundless Bio is an oncology company developing drugs that target extrachromosomal DNA (ecDNA), which promotes tumor growth and resistance. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance to the broader market.
Change in the price of a company, segment, and market as a whole per day
BOLD - Daily change in the company's share price Boundless Bio Inc.
For Boundless Bio, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials of its drugs targeting extrachromosomal DNA.
Daily change in the price of a set of shares in a market segment - Dna
Boundless Bio, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with BOLD, with its unique approach to cancer treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Boundless Bio is a biotech company focused on treating cancers caused by specific genetic abnormalities (ecDNA). Its shares are a bet on cutting-edge science. Their high volatility is part of the dynamics of the innovative sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Boundless Bio Inc.
Boundless Bio, Inc.'s year-over-year performance is a story of developing a new approach to cancer treatment. Its 12-month market cap depends entirely on progress in clinical trials of its drugs targeting extrachromosomal DNA (ecDNA), a key driver of treatment resistance in many aggressive tumors.
Annual dynamics of market capitalization of the market segment - Dna
Boundless Bio, a recent IPO, is a biotech company developing innovative cancer treatments. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Boundless Bio is a clinical-stage biotech company whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Boundless Bio Inc.
Boundless Bio is an oncology company developing drugs targeting extrachromosomal DNA (ecDNA). Being an early-stage company, its monthly valuation is based on the potential of its innovative scientific platform. Progress in preclinical studies is the main driver.
Monthly dynamics of market capitalization of the market segment - Dna
Boundless Bio is a biotech company pioneering the treatment of cancers caused by extrachromosomal DNA (ecDNA) amplification. This is a completely new approach to oncology. The dynamics of the biotech sector reflect investors' hopes for a breakthrough. Boundless Bio's story is a bet on cutting-edge science, which, if successful, could unlock a whole new class of drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Boundless Bio, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted therapies for the treatment of oncogene-amplified tumors. The company's future depends on the success of its R&D. The broader market chart serves only as a backdrop to understand how its cutting-edge scientific approach to treating specific cancer types impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Boundless Bio Inc.
Boundless Bio, a biotech company focused on combating oncogenic extrachromosomal DNA (ecDNA), is experiencing the high volatility typical of breakthrough technologies. Its weekly stock price is reflecting a sharp reaction to news about its research progress and early clinical trial data, which will determine the future of this new approach to oncology.
Weekly dynamics of market capitalization of the market segment - Dna
Boundless Bio operates in the revolutionary sector of targeted cancer therapy, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether BOLD is perceived by the market as a leader in this movement or simply part of it, moving along with the mainstream.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Boundless Bio often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how BOLD shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
BOLD - Market capitalization of the company Boundless Bio Inc.
Boundless Bio's market cap is a visual representation of the cutting edge of oncology. This biotech's chart reflects investors' faith in its approach to treating cancers associated with extrachromosomal DNA. Its dynamics reflect a bet on a scientific breakthrough, where every research result could radically change the company's valuation.
BOLD - Share of the company's market capitalization Boundless Bio Inc. within the market segment - Dna
Boundless Bio is a biotech company developing drugs to treat cancers caused by extrachromosomal DNA (ecDNA) amplification. Its market share in the oncology sector is based on this cutting-edge scientific approach. The chart shows how the market perceives its potential to combat the most aggressive tumors.
Market capitalization of the market segment - Dna
Boundless Bio is a biotech company focused on fighting cancers caused by special extrachromosomal DNA (ecDNA). The chart below shows the market capitalization of the DNA technology sector. This is the valuation of one of the most cutting-edge areas in oncology, potentially changing the rules of the game.
Market capitalization of all companies included in a broad market index - GURU.Markets
Boundless Bio is an oncology company developing drugs that target extrachromosomal DNA (ecDNA), which helps cancer cells become resistant to therapy. Its market cap is a bet on this new approach. The chart below shows the weight of cutting-edge science.
Book value capitalization of the company, segment and market as a whole
BOLD - Book value capitalization of the company Boundless Bio Inc.
Boundless Bio's foundation is the capital for a groundbreaking approach to cancer treatment. The company's book value consists of patents for its technology for targeting extrachromosomal DNA (ecDNA), which causes resistance to therapy, and funds for R&D. The chart below shows how the company is building a financial foundation for its breakthrough research.
BOLD - Share of the company's book capitalization Boundless Bio Inc. within the market segment - Dna
Boundless Bio relies on its cutting-edge research laboratories to develop cancer treatments. This scientific infrastructure is its key tangible asset. The S_BCap_Seg chart shows its share of the innovative biotech sector's physical assets.
Market segment balance sheet capitalization - Dna
Boundless Bio is a biotech company developing drugs to treat cancer caused by extrachromosomal DNA. Its value lies in its unique scientific approach and patents. A book value chart shows that its assets are almost entirely intangible, reflecting a focus on research rather than production.
Book value of all companies included in the broad market index - GURU.Markets
Boundless Bio's book value represents a scientific arsenal for combating cancer resistance. The company's assets include cutting-edge laboratories, an extrachromosomal DNA (ecDNA) detection platform, and capital for targeted drug development. This is the foundation for addressing one of the most challenging problems in modern oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Boundless Bio Inc.
Boundless Bio is a biotech company targeting extrachromosomal oncogenes. Its book value is primarily cash, while its market capitalization reflects investors' faith in its innovative scientific approach to cancer treatment. It's a pure valuation of the potential for breakthrough science.
Market to book capitalization ratio in a market segment - Dna
Boundless Bio is a biotech company focused on treating cancer using an innovative approach to DNA. Its value lies in its scientific platform. The chart demonstrates how market expectations for its technology outpace its tangible assets. It's a classic example of biotech valuation based on hope.
Market to book capitalization ratio for the market as a whole
Boundless Bio is a biotech company focused on treating cancer using an innovative approach to tumor genetics. Its value is determined solely by the potential of its scientific platform. The chart shows how investors value the "hope" of a medical breakthrough, resulting in a valuation that is a multiple of its book value.
Debts of the company, segment and market as a whole
BOLD - Company debts Boundless Bio Inc.
Boundless Bio, an early-stage biotech company, is using debt, likely venture capital, to finance its innovative platform. This chart shows capital allocated to preclinical research and drug development targeting specific genetic abnormalities in cancer cells.
Market segment debts - Dna
Boundless Bio is a biotechnology company developing drugs for cancers caused by extrachromosomal DNA. Being in early-stage clinical trials, the company has no sales revenue. This chart reflects its financial structure, which is based entirely on equity capital to fund cutting-edge scientific research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Boundless Bio Inc.
Boundless Bio is a biotech company specializing in treating cancers caused by extrachromosomal DNA. This chart shows its leverage. For a company at the forefront of science, debt can accelerate research, but it can also create pressure. The chart provides insight into the level of risk management considers acceptable.
Market segment debt to market segment book capitalization - Dna
Boundless Bio is a biotech company specializing in cancer treatment using innovative genetic approaches. This chart for the science-intensive DNA technology industry shows how much capital it is raising to fund breakthrough research. It helps understand whether the company's debt is an investment in the future or a consequence of high costs.
Debt to book value of all companies in the market
Boundless Bio is a biotech company focused on fighting cancer by developing drugs that target extrachromosomal DNA (ecDNA). This chart, showing the overall debt-to-book capitalization ratio, reflects the market's willingness to fund breakthrough but capital-intensive technologies that directly impact the success and speed of Boundless Bio's research.
P/E of the company, segment and market as a whole
P/E - Boundless Bio Inc.
Boundless Bio is a biotech company focused on treating cancers caused by extrachromosomal DNA (ecDNA), which contributes to tumor resistance to therapy. This chart reflects its belief in its cutting-edge scientific approach. The high value of this indicator reflects the high expectations associated with developing a first-in-class treatment for this challenging patient population.
P/E of the market segment - Dna
Boundless Bio is a biotech company operating at the cutting edge of science. This chart shows the average P/E for the biotech sector. A company's P/E is higher than average, indicating that investors consider its focus on ecDNA particularly promising and are willing to pay a premium for its potential compared to other biotechs.
P/E of the market as a whole
Boundless Bio is a biotech company focused on treating cancers caused by extrachromosomal DNA (ecDNA) amplification. This is a novel and promising approach to oncology. The company's valuation is a bet on the success of its groundbreaking science. This chart shows the overall interest in innovation. It helps understand whether Boundless Bio stands out with its unique technology and how the market perceives its scientific risk.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Boundless Bio Inc.
Boundless Bio is a biotechnology company specializing in the development of treatments for cancers caused by extrachromosomal DNA (ecDNA). The chart shows investor expectations based on the potential of this new scientific approach. Future revenue depends on the success of clinical trials and the ability to develop a new class of anticancer drugs.
%20P%2FE%20Boundless%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Boundless-Bio-Inc.&v=1772553004453 "Chart of the company's future (projected) P/E Boundless Bio Inc.")
Future (projected) P/E of the market segment - Dna
Boundless Bio is a biopharmaceutical company developing drugs to treat cancers caused by extrachromosomal DNA (ecDNA) amplification. This chart shows analyst estimates for its future revenue, reflecting its belief in its innovative approach to treating the most aggressive cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772553004602 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Boundless Bio is a biotechnology company developing a novel approach to cancer treatment by targeting extrachromosomal DNA (ecDNA). This is cutting-edge science. The company's valuation is not tied to general market forecasts, but is entirely dependent on the success of its innovative platform and clinical trial data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772553004657 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Boundless Bio Inc.
Boundless Bio is a biotech company developing a new class of cancer drugs targeting extrachromosomal DNA (ecDNA), which drives tumor growth. While in the research phase, the company incurs significant R&D expenditures. This chart reflects its investment in a novel approach to cancer treatment that has the potential to generate future profits.
Profit of companies in the market segment - Dna
Boundless Bio, Inc. is a biopharmaceutical company developing targeted therapies for cancers caused by extrachromosomal DNA (ecDNA). This chart shows the profitability of its niche. The company is a pioneer in this field. Its R&D costs impact its current overall profitability, but research success could open up entirely new avenues for cancer treatment.
Overall market profit
Boundless Bio is a biopharmaceutical company pioneering the development of treatments for cancers caused by extrachromosomal DNA. Its value and future are determined by scientific discoveries and the success of clinical trials. This chart illustrates general economic cycles, with Boundless Bio operating at the forefront of genetics, where value is created independent of the market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Boundless Bio Inc.
Boundless Bio is a biopharmaceutical company pioneering the development of drugs targeting extrachromosomal DNA (ecDNA), which drives the growth of many cancers. This chart reflects analysts' future earnings expectations based on the potential of this revolutionary approach. It demonstrates the market's confidence in the company's ability to create a new class of oncology drugs.
%20profit%20of%20the%20company%20Boundless%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Boundless-Bio-Inc.&v=1772553004946 "Graph of future (projected) profit of the company Boundless Bio Inc.")
Future (predicted) profit of companies in the market segment - Dna
Boundless Bio, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of oncological diseases caused by extrachromosomal DNA (ecDNA). This chart shows forecasts for the DNA segment of the pharmaceutical industry. It reflects expectations for breakthroughs in cancer genetics, where Boundless Bio operates at the cutting edge of science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772553004989 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Boundless Bio is a biotech company specializing in the treatment of cancer caused by extrachromosomal DNA. Their success depends on scientific breakthroughs and the ability to fund research. The market's total return forecast reflects investors' risk appetite: during growth periods, they are more willing to back innovative but capital-intensive companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772553005008 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Boundless Bio Inc.
Boundless Bio is a biotech company developing therapies to treat cancers caused by specific genetic mutations. A P/S is not used before market entry. However, after launch, it will demonstrate how highly investors value its innovative approach and commercial potential in personalized medicine.
P/S market segment - Dna
Boundless Bio is a biotech company developing innovative cancer treatments that target specific genetic abnormalities in tumor cells. Their approach to personalized medicine is at the forefront of science. This chart reflects how investors view their scientific platform and the potential for future revenue from breakthrough therapies.
P/S of the market as a whole
Boundless Bio is a biotech company focused on treating cancers caused by specific genetic abnormalities (ecDNA). It has no revenue, and its valuation is based on the potential of its innovative platform. This chart, reflecting the valuation of companies with real revenues, clearly demonstrates that investing in Boundless Bio is a bet on cutting-edge science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Boundless Bio Inc.
Boundless Bio is a biotech company pioneering the development of drugs that target extrachromosomal DNA (ecDNA), which promotes cancer growth and resistance. This chart reflects investor expectations for future revenue from this entirely new class of oncology drugs, a bet on cutting-edge science.
%20P%2FS%20Boundless%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Boundless-Bio-Inc.&v=1772553005267 "The graph of the company's future (projected) P/S Boundless Bio Inc.")
Future (projected) P/S of the market segment - Dna
Boundless Bio, Inc. is an oncology company focused on developing treatments for patients with tumors driven by extrachromosomal DNA (ecDNA). This chart shows how the market perceives the future commercial potential of its innovative approach. It compares it to other DNA-focused companies, reflecting the belief in its ability to create a new class of drugs.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772553005359 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Boundless Bio is a biotech company developing a new approach to cancer treatment that targets specific genetic mutations. It's at the forefront of oncology research. This chart shows revenue expectations for the entire market, and Boundless Bio exemplifies how faith in breakthrough genetic technologies is driving long-term investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772553005396 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Boundless Bio Inc.
Boundless Bio is a clinical-stage oncology company focused on developing treatments for patients with extrachromosomal DNA (ecDNA)-driven gene amplification. Because its therapies are in development, sales revenue is not included in this chart. Future revenue is dependent on the success of clinical trials and drug commercialization.
Sales of companies in the market segment - Dna
Boundless Bio is a biotech company focused on treating cancer. At this stage of development, its revenue is likely generated through partnerships with major pharmaceutical companies. This chart allows investors to assess the level of financial support, reflecting their partners' faith in the company's scientific approach.
Overall market sales
Boundless Bio is a biotech company focused on developing treatments for cancers caused by specific genetic abnormalities. Its success depends on progress in research and clinical trials. This market performance chart is not relevant for valuing a company whose value is created in the laboratory, not in the marketplace.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Boundless Bio Inc.
Boundless Bio is a biopharmaceutical company developing therapies for cancers caused by specific genetic abnormalities (ecDNA). Its revenue forecast is based on expected clinical trial success. This chart reflects analysts' confidence in its innovative approach to targeted oncology.
%20sales%20of%20the%20company%20Boundless%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Boundless-Bio-Inc.&v=1772553005524 "Schedule of future (projected) sales of the company Boundless Bio Inc.")
Future (projected) sales of companies in the market segment - Dna
Boundless Bio is an oncology company focused on fighting cancer through the study of extrachromosomal DNA (ecDNA). This chart shows projected revenue for the gene therapy segment. It reflects the expected growth of the precision oncology market, which is key to the commercialization of Boundless Bio's cutting-edge scientific approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772553005529 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Boundless Bio is a biopharmaceutical company focused on developing drugs to treat cancers caused by extrachromosomal DNA amplification. Success depends on science. This graph of overall market expectations reflects the investment climate. This positive environment facilitates raising the hundreds of millions of dollars needed to bring an oncology drug to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772553005737 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Boundless Bio Inc.
Boundless Bio is a clinical-stage biopharmaceutical company developing drugs targeting extrachromosomal DNA (ecDNA) for the treatment of cancer. This chart reflects its current research focus. It doesn't show profits, but rather investments in breakthrough science, the success of which determines the company's future value.
Market segment marginality - Dna
Boundless Bio is a biopharmaceutical company focused on fighting cancer by targeting extrachromosomal DNA (ecDNA), which drives tumor growth. This chart shows the average profitability in the advanced biotech sector. It helps assess the financial advantage the company's unique scientific approach can provide compared to industry norms.
Market marginality as a whole
Boundless Bio, Inc. is another oncology biotech company specializing in the treatment of cancers caused by extrachromosomal DNA. This chart of the overall profitability of traditional companies serves only as a backdrop to understand the risk and unpredictability of investing in cutting-edge science, where the stakes are highest.
Employees in the company, segment and market as a whole
Number of employees in the company Boundless Bio Inc.
Boundless Bio is a biotech company focused on developing treatments for cancers caused by extrachromosomal DNA. Its team of innovative scientists is on hand. The growth in this chart reflects increased investment in its cutting-edge scientific platform and progress in preclinical research, which is critical to the company's future.
Share of the company's employees Boundless Bio Inc. within the market segment - Dna
Boundless Bio is a biopharmaceutical company developing a new class of targeted cancer therapies targeting extrachromosomal DNA (ecDNA). This chart highlights its unique scientific approach. It shows how many leading geneticists and oncologists working at the forefront of ecDNA research Boundless Bio is bringing together to combat cancer treatment resistance.
Number of employees in the market segment - Dna
Boundless Bio, Inc. is a biopharmaceutical company developing drugs to treat cancers caused by extrachromosomal DNA (ecDNA). This chart shows employment in the DNA research sector. The growing number of geneticists and oncologists in this cutting-edge field reflects breakthroughs in understanding cancer mechanisms, opening up new therapeutic targets.
Number of employees in the market as a whole
Boundless Bio, Inc. is a biotech company working on the treatment of cancers caused by extrachromosomal DNA. This is at the cutting edge of science, requiring unique specialists. This graph illustrates the overall labor market, where such innovative startups, although small, are an indicator of future technological developments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Boundless Bio Inc. (BOLD)
Boundless Bio is a biotech company whose value is determined by future discoveries. This chart shows the market premium placed on cutting-edge scientific research. The company's enormous market capitalization per employee reflects investors' faith that a small team of scientists can create intellectual property worth billions of dollars.
%20of%20the%20company%20Boundless%20Bio%20Inc.%20(BOLD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Boundless-Bio-Inc.-BOLD&v=1772553006474 "Chart of market capitalization per employee (in thousands of dollars) of the company Boundless Bio Inc. (BOLD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Boundless Bio develops cancer drugs targeting specific genetic abnormalities. In such a knowledge-intensive business, the company's market capitalization per employee reflects the market's belief in the breakthrough potential of its platform. If this metric is higher than that of its competitors, investors highly value its intellectual property and its chances of clinical success.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772553006552 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Boundless Bio is a biotech company specializing in developing treatments for cancers caused by specific genetic mutations. It's at the cutting edge of oncology. This chart reflects the high investor esteem of each scientist whose research could lead to the creation of a new class of targeted therapy for patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772553006589 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Boundless Bio Inc. (BOLD)
Boundless Bio is a biotech company attacking cancer through a novel target—extrachromosomal DNA (ecDNA). This is cutting-edge science and pure R&D. This graph is negative during the preclinical and clinical trials. It shows how much the company is investing in each scientist to test this revolutionary cancer treatment hypothesis.
%20Chart%20Boundless%20Bio%20Inc.%20(BOLD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Boundless-Bio-Inc.-BOLD&v=1772553006590 "Company Profit Per Employee (in thousands of dollars) Chart Boundless Bio Inc. (BOLD)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Boundless Bio is a biotech company developing cancer therapies targeting extrachromosomal DNA (ecDNA). This graph captures the potential value of their innovative approach. It demonstrates how a small but highly specialized team of scientists can create a therapy with enormous market potential, a benchmark for effectiveness in advanced oncology.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772553006642 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Boundless Bio is a biopharmaceutical company focused on oncology and the treatment of cancers associated with extrachromosomal DNA (ecDNA). This metric reflects Boundless Bio's R&D intensity. It shows how much the company invests in breakthrough research per scientist, striving to create a new class of drugs and achieve a high return on this investment in the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772553006678 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Boundless Bio Inc. (BOLD)
Boundless Bio is a clinical-stage biotech company. This chart is not an indicator of current performance, as there is no revenue. It illustrates the company's investment in research. If its oncology drugs are approved, this metric will demonstrate a significant financial return on the intellectual property it has developed.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Boundless-Bio-Inc.-BOLD&v=1772553006776 "Sales chart per company employee Boundless Bio Inc. (BOLD)")
Sales per employee in the market segment - Dna
Boundless Bio (BOLD) is an oncology company specializing in the treatment of cancers caused by extrachromosomal DNA (ecDNA) amplification, a novel therapeutic approach. This chart shows average revenue per employee in the pharmaceutical segment. Being in the R&D stage, Boundless Bio has no commercial sales. Comparison with the benchmark emphasizes their focus on cutting-edge science rather than current sales productivity.
Sales per employee for the market as a whole
Boundless Bio is a biotech company specializing in oncology (cancer treatment). Like other clinical-stage companies, Boundless Bio does not yet have commercial revenue. This metric does not reflect current performance. Investors are focused on their scientific developments, which could one day lead to a sharp increase in this metric.
Short shares by company, segment and market as a whole
Shares shorted by company Boundless Bio Inc. (BOLD)
Boundless Bio is a biotech company attacking cancer from a new angle: they're developing drugs that target extrachromosomal DNA (ecDNA), which helps tumors grow. This is cutting-edge science, but it's unproven. This chart reflects the skepticism of investors who are betting that this hypothesis will prove incorrect or that their drugs will be too toxic.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Boundless-Bio-Inc.-BOLD&v=1772553006930 "Short Shares Chart for the Company Boundless Bio Inc. (BOLD)")
Shares shorted by market segment - Dna
Boundless Bio (BOLD) is a biotech company that attacks cancer through a completely new target: extrachromosomal DNA (ecDNA). This is a highly experimental field. This indicator reflects pessimism in the genetic medicine sector. The growing short position in the industry indicates that investors distrust "science fiction" and consider such approaches too risky. For BOLD, this is a signal that the market is skeptical of the very foundation of its technology.
Shares shorted by the overall market
Boundless Bio is an oncology company developing drugs against specific DNA mutations (ecDNA). This is cutting-edge, but very early-stage research. This chart reflects the overall market pessimism. When fear dominates, investors are unwilling to fund fundamental science. They are selling off BOLD shares, as the path from ecDNA discovery to a commercial drug will take many years and hundreds of millions.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Boundless Bio Inc. (BOLD)
Boundless Bio (BOLD) is a biotech company attacking cancer by targeting ecDNA, a novel approach. Shares of such companies are driven by anticipation for research. This indicator measures the strength of these expectations. It shows when the stock is "overheated" (above 70) or "oversold" (below 30), helping to assess whether investor sentiment has gone too far.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Boundless-Bio-Inc.-BOLD&v=1772553007140 "RSI 14 indicator chart for the company's stock Boundless Bio Inc. (BOLD)")
RSI 14 Market Segment - Dna
Boundless Bio (BOLD) is an oncology company attacking cancer from a unique angle: they target extrachromosomal DNA (ecDNA), which helps tumors rapidly develop resistance. This chart tracks the collective sentiment in the DNA/Oncology sector. It shows when the entire industry is overheated by hype around breakthroughs or oversold by setbacks.
RSI 14 for the overall market
Boundless Bio (BOLD) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BOLD (Boundless Bio Inc.)
Boundless Bio (BOLD) is an oncology company developing targeted therapies that target extrachromosomal DNA (ecDNA), which is believed to help cancer develop resistance. This chart shows the speculative average price target from analysts based on their belief in this emerging scientific R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BOLD-Boundless-Bio-Inc.&v=1772553007393 "A chart showing analyst consensus forecasts for the expected stock price. BOLD (Boundless Bio Inc.)")
The difference between the consensus estimate and the actual stock price BOLD (Boundless Bio Inc.)
Boundless Bio is a biotech company attacking cancer from a new angle. It develops drugs against "ecDNA"—the extrachromosomal DNA that tumors use to survive. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this breakthrough science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BOLD-Boundless-Bio-Inc.&v=1772553007403 "A chart showing the difference between the consensus forecast and the actual stock price. BOLD (Boundless Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Boundless Bio (BOLD) is an oncology company developing drugs that target "ecDNA"—a specific type of DNA in cancer cells that makes them resistant to treatment. This chart shows general expectations for the DNA technology sector, reflecting whether experts believe in this cutting-edge approach to combating cancer resistance.
Analysts' consensus forecast for the overall market share price
Boundless Bio (BOLD) is a biopharmaceutical company attacking cancer from the flank. They focus on "ecDNA"—a specialized DNA that helps tumors grow rapidly and become resistant to treatment. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Boundless Bio Inc.
Boundless Bio (BOLD) is a biotech R&D company attacking cancer from a new angle. They target not DNA mutations, but ecDNA—extrachromosomal DNA—which cancer uses to amplify genes and rapidly become resistant to treatment. This chart is a clear indicator of their deep science. It reflects the market's faith in this new, disruptive (and risky) oncology strategy.
AKIMA Market Segment Index - Dna
Boundless Bio (BOLD) is an oncology company targeting what was previously considered incurable. They are developing drugs against extrachromosomal DNA (ecDNA), which helps cancer rapidly develop drug resistance. The chart shows the segment average, helping investors assess how this cutting-edge scientific strategy compares to the average.
The AKIM Index for the overall market
Boundless Bio is an oncology company studying extrachromosomal DNA (ecDNA), a key driver of cancer aggressiveness. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this emerging field of cancer biology.
